- Home
- ANVS vs BNTC Comparison
ANVS vs BNTC Comparison
Compare ANVS & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | BNTC |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 411.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANVS | BNTC |
|---|---|---|
| Price | $2.30 | $10.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $13.50 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 493.8K | 125.2K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.39 | ★ 80.94 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $9.85 |
| 52 Week High | $5.50 | $17.15 |
Technical Indicators
Market Signals| Indicator | ANVS | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 46.00 |
| Support Level | $2.10 | $9.91 |
| Resistance Level | $2.99 | $13.27 |
| Average True Range (ATR) | 0.24 | 0.58 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 41.98 | 45.65 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.